Covid19
Conditions
Brief summary
This study is aimed to investigate the treatment vitamin D3 as complementary therapy with routine care for early mild symptoms of COVID-19 in outpatients setting.
Detailed description
There is currently no specific early-stage therapeutic treatment available for COVID-19. Vitamin D3 is a strong antioxidant, and anti-inflammatory/immunomodulatory agent. The present study is aimed to investigate the treatment benefits of vitamin D3 as add-on therapy to the routine care for early mild symptoms of COVID-19 infection in outpatients setting.
Interventions
DRUGStandard of care
Standard of care treatment as per the hospital guidelines
DIETARY_SUPPLEMENTVitamin D3
A daily dose of 5000 IU vitamin D3 for 7 days.
Sponsors
Liaquat University of Medical & Health Sciences
Ayub Teaching Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must be 18 years of age or older, of either gender * Patients must be tested positive for SARS-CoV-2 by RT-PCR * Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes withshaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc. * Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening * Patients must be under the care of a Physician for diagnosis of COVID-19 * Patients who have signed informed consent
Exclusion criteria
* Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin * Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis * Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure * Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. * Patients with gallstone obstruction * Hypothyroid suppering patients * Patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/L); * Pregnant patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SARS-CoV-2 Negativity by RT-PCR | From day 1 to day 14 | The numbers of patients that tests COVID-19 negative |
| COVID-19 symptoms improvement | From day 1 to day 14 | The numbers of patients whose COVID-19 symptoms are subsided |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in LDH level | From day 1 to day 14 | Improvement in blood LDH level |
| Changes in CRP level | From day 1 to day 14 | Improvement in blood CRP level |
| Changes in full blood count | From day 1 to day 14 | Improvement in full blood count |
| Changes in ferritin level | From day 1 to day 14 | Improvement in blood ferritin level |
| Changes in D-dimer level | From day 1 to day 14 | Improvement in blood D-dimer level |
Countries
Pakistan
Contacts
Primary ContactDr. Zeeshan Haroon, MBBS
Outcome results
None listed